Dexamethasone intravitreal implants : characterization, manufacture, and elucidation of drug release mechanisms

dc.contributor.advisorZhang, Feng, Ph. D.
dc.contributor.committeeMemberLynd, Nathaniel A
dc.contributor.committeeMemberWilliams III, Robert O
dc.contributor.committeeMemberSmyth, Hugh DC
dc.creatorCostello, Mark Allen
dc.date.accessioned2024-05-15T01:22:27Z
dc.date.available2024-05-15T01:22:27Z
dc.date.issued2023-08
dc.date.submittedAugust 2023
dc.date.updated2024-05-15T01:22:27Z
dc.description.abstractLong-acting injectable products based on the biodegradable polymer poly(lactide-co-glycolide) (PLGA) have been available in the USA since 1989, with more than 20 PLGA–based formulations approved for use to date. Despite the clinical and commercial success of many of these drug products, no generic formulations have gained FDA approval at the time of this writing. The lack of PLGA–based generics can largely be attributed to the technical challenges associated with development of formulations with drug release profiles equivalent to the reference product. Despite extensive study of the drug release mechanisms of PLGA, the inherent complexity of the copolymer is largely to blame for the challenges associated with generic product development. In this work, the FDA–approved product Ozurdex (dexamethasone intravitreal implant) was used as a model system to help address the challenges associated with generic product development of PLGA–based solid implants. Ozurdex is a small, rod-shaped implant (0.46 mm diameter, 6 mm long) formulated to deliver the corticosteroid dexamethasone to the posterior segment of the eye for 3–6 months. Ozurdex was thoroughly characterized and shown to be a porous implant consisting of a two-phase system of dexamethasone crystals embedded within a PLGA matrix due to a limited drug-polymer interaction. Compositionally equivalent, reverse-engineered implants were produced using a continuous hot-melt extrusion process that required careful control to manufacture implants structurally equivalent to Ozurdex. The drug release mechanisms of the reverse-engineered implants were studied in detail using a variety of analytical techniques to examine the implant throughout the drug release period. This work also demonstrated how sourcing PLGAs with similar, but subtly different, physicochemical properties can affect the manufacture and drug release kinetics of dexamethasone intravitreal implants.
dc.description.departmentPharmaceutical Sciences
dc.format.mimetypeapplication/pdf
dc.identifier.uri
dc.identifier.urihttps://hdl.handle.net/2152/125329
dc.identifier.urihttps://doi.org/10.26153/tsw/51920
dc.language.isoen
dc.subjectImplant
dc.subjectDexamethasone
dc.subjectPLGA
dc.titleDexamethasone intravitreal implants : characterization, manufacture, and elucidation of drug release mechanisms
dc.typeThesis
dc.type.materialtext
thesis.degree.departmentPharmaceutical Sciences
thesis.degree.grantorThe University of Texas at Austin
thesis.degree.nameDoctor of Philosophy

Access full-text files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
COSTELLO-PRIMARY-2024-1.pdf
Size:
5.01 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 2 of 2
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.84 KB
Format:
Plain Text
Description:
No Thumbnail Available
Name:
PROQUEST_LICENSE.txt
Size:
4.45 KB
Format:
Plain Text
Description: